Kathy Miller

27PUBLICATIONS
195CO-AUTHORS
Epidemiological modellingMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Satisfiability and optimisationPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|May 30, 2026
Impact of patient-reported taxane-induced peripheral neuropathy on dose reductions or worsening quality of life in Black women with breast cancer: Analysis from ECOG-ACRIN EAZ171.

|Apr 14, 2026
A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer.

Kathy D Miller, Alexandra Thomas, Sandra Althouse

|Feb 25, 2026
A Co-Design Study Developing an Early Prototype Intervention to Support Oral Anticancer Medication Use in Breast Cancer.

Yejin Seo, Karen Suchanek Hudmon, Kellie Jones Weddle

|Nov 21, 2025
Carboplatin for Premenopausal Triple-Negative Breast Cancer: Time to Rethink the Neoadjuvant Standard?

Rina K Yadav, Kathy D Miller

|Oct 02, 2025
Bringing Trustworthy Artificial Intelligence to the Clinical Forefront at <i>JCO</i>: A Guide for Studies Testing Artificial Intelligence Models.

Ravi B Parikh, Alexia Iasonos, Andrew Ko

|Aug 25, 2025
Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.

Lorenzo Gerratana, Carolina Reduzzi, Yue Ren

Pageof 5

Frequent Collaborators

5 joint publications

Bryan P Schneider

5 joint publications

Tarah J Ballinger

4 joint publications

Antonio C Wolff

4 joint publications

Angela DeMichele